the basis of T/R in the Pro­tocol [Regulatives / Guidelines]

posted by mittyri – Russia, 2014-03-14 22:08 (3688 d 10:26 ago) – Posting: # 12631
Views: 5,664

Dear Helmut,

Thank you for the inestimable contribution to my (and others) knowledge in BEQ :cool:

❝ By “pilot” I meant studies the sponsor performed or have access to in an acquired dossier. Only such studies can be assesses for the quality of data (clinical performance, bioanalytics, …).


If I understand right, you state in the protocol phrases like that:
According to the earlier performed by sponsor study, T/R ratio could be assumed as 0.92%.
How could I prove to the assessor that "pilot" study is really performed? As a sponsor I can write that I performed the study in another market, but assessment report isn't published (no links)

❝ Once the Austrian agency AGES did not like the sample size we stated in the protocol: “It is not acceptable to perform the study in only 16 sub­jects when most of the BE studies of XYZ are performed in more than 30.” Hey, it was a pilot study… Case closed. :-D


Nice example :-D
In this case, did you "hit the jackpot" (by the luck CI's were in the borders)?

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
22,987 posts in 4,824 threads, 1,663 registered users;
102 visitors (0 registered, 102 guests [including 6 identified bots]).
Forum time: 09:34 CEST (Europe/Vienna)

The only way to comprehend what mathematicians mean by Infinity
is to contemplate the extent of human stupidity.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5